Hematologic Oncology

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..

Topline results from the phase 1 European MB-105 clinical trial showed that new safety results for annamycin, a next-generation anthracycline, are in keeping with previous findings for patients with relapsed/refractory acute myeloid leukemia.

The combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cell lymphoma, according to preliminary findings from the phase 2b VITALIZE trial.

Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.

Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.

The CAR T-cell therapy brexucabtagene autoleucel produced a median overall survival of 26 months in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.

Dr Komrokji leads a discussion on emerging data on how p53 mutations and chromosome 5q deletions may affect prognosis, treatment response, and outcomes for patients with MDS.

Expert panelists reflect on the case presented by Dr Garcia-Manero and share their unique perspectives on how they might have approached treatment and followup for this patient in their own practice.

In this fifth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, reviews the implications of up-front vs delayed transplant on survival, quality of life, and risk of secondary malignancies in newly diagnosed, multiple myeloma.

Dr Komrokji summarizes the remaining unmet needs in the treatment of MF, including suboptimal responses to JAK2 inhibitors, and comments on data from ongoing trials that may address these needs.

A comprehensive review of the treatment landscape for myelofibrosis (MF) and recent ASCO and ASH data updates on JAK2 inhibitors.

Treatment with crovalimab led to disease control through transfusion avoidance and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who have not been previously treated with complement inhibitors.

Closing out their discussion on tumor lysis syndrome management, James Short, MD, and John Reagan, MD, highlight unmet needs and future evolutions in the treatment landscape.

Expert perspectives on the emergence of FLT3-targeted therapies and their role in the first-line setting of acute myeloid leukemia management.

A brief review of the differences that might be observed between tumor lysis syndrome management in an academic versus community setting.

Centering focus on first-line treatment modalities, panelists highlight the ongoing role of intensive chemotherapy in the management of AML.

Revumenib resulted in deep response rates, facilitating subsequent transplant in patients with KMT2A-rearranged or NMP1-mutant, relapsed/refractory acute myeloid leukemia.

Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.

Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.

Eunice Wang, MD, discusses the utility of minimal residual disease testing in hematologic malignancies and challenges associated with expanding its role in clinical practice for acute myeloid leukemia.

Dr Rosenthal discusses the care of adolescent and young adult patients with Hodgkin lymphoma, the discrepancies between pediatric and adult oncologists that result in differing treatment approaches, and common concerns these patients have as they navigate their diagnosis and treatment alongside other life changes.

A brief review of T-Cell acute lymphoblastic leukemia and emerging novel therapies that may improve upon its existent treatment armamentarium.

Naveen Pemmaraju, MD, highlights unmet needs in the setting of myelofibrosis management and looks toward future evolutions in the treatment paradigm.

Expert perspectives on specific subsets of the REFINE study, which combined ruxolitinib with navitoclax in patients diagnosed with myelofibrosis.

Guillermo Garcia-Manero, MD presents a case of lower-risk MDS with chromosome 5q and 20q deletions and a p53 mutation, and discusses first- and second-line treatment selection.

Shifting his focus to treatment strategies in myelofibrosis, Naveen Pemmaraju, MD, reviews the current drug armamentarium and explains how it ties into disease modification.

Expert hematologist-oncologist Naveen Pemmaraju, MD, highlights current strategies in diagnosing and stratifying patients with myelofibrosis.

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Dr Platzbecker outlines available second-line therapies for symptomatic anemia in patients with lower-risk MDS, highlighting differences in availability between the United States and Europe.